Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial

The current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-interv...

Full description

Bibliographic Details
Main Authors: Haijun Deng MD, PhD, Dong Liu MBBS, Xiangming Mao MD, PhD, Xiaoliang Lan MD, Hao Liu MD, PhD, Guoxin Li MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2017-05-01
Series:American Journal of Men's Health
Online Access:https://doi.org/10.1177/1557988316665084
id doaj-3117621aa2554157828ef8e16cd208bc
record_format Article
spelling doaj-3117621aa2554157828ef8e16cd208bc2020-11-25T03:03:15ZengSAGE PublishingAmerican Journal of Men's Health1557-98831557-98912017-05-011110.1177/1557988316665084Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled TrialHaijun Deng MD, PhD0Dong Liu MBBS1Xiangming Mao MD, PhD2Xiaoliang Lan MD3Hao Liu MD, PhD4Guoxin Li MD, PhD5NanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaPeking University Shenzhen Hospital, Shenzhen, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaThe current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-intervention, nightly use of sildenafil 25 mg for 3 months after surgery, or concurrent use of nightly sildenafil 25 mg/day for 3 months and a vacuum erection device (VED) 10 to 15 minutes/day for 3 months—in a nonrandomized fashion. All participants had a follow-up of over 12 months prospectively, and patients had baseline, 3-, 6-, and 12-month assessment based on the International Index of Erectile Function–5 (IIEF-5). Seventy-one cases were included in final analyses. In the no-intervention group, the mean baseline IIEF-5 score of 21.9 decreased rapidly to 5.0 at 3 months ( p < .001), 9.2 at 6 months ( p < .001), and stayed at 10.9 at 12 months ( p < .001). In the single therapy group, the mean baseline IIEF-5 score of 22.4 decreased dramatically to 9.0 at 3 months ( p < .001), 14.9 at 6 months ( p = .005), and stayed at 15.1 at 12 months ( p = .005). In the combined therapy group, the mean baseline IIEF-5 score of 23.0 decreased slightly to 15.0 at 3 months ( p = .005), 18.0 at 6 months ( p = .038), and maintained at 18.7 at 12 months ( p = .163). Findings suggested an over 50% decline in the quality of erection function of the patients after LNRP. The early use of PDE-5i alone or combined use of PDE-5i and VED after LNRP maintained erectile function at 12 months.https://doi.org/10.1177/1557988316665084
collection DOAJ
language English
format Article
sources DOAJ
author Haijun Deng MD, PhD
Dong Liu MBBS
Xiangming Mao MD, PhD
Xiaoliang Lan MD
Hao Liu MD, PhD
Guoxin Li MD, PhD
spellingShingle Haijun Deng MD, PhD
Dong Liu MBBS
Xiangming Mao MD, PhD
Xiaoliang Lan MD
Hao Liu MD, PhD
Guoxin Li MD, PhD
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
American Journal of Men's Health
author_facet Haijun Deng MD, PhD
Dong Liu MBBS
Xiangming Mao MD, PhD
Xiaoliang Lan MD
Hao Liu MD, PhD
Guoxin Li MD, PhD
author_sort Haijun Deng MD, PhD
title Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
title_short Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
title_full Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
title_fullStr Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
title_full_unstemmed Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
title_sort phosphodiesterase-5 inhibitors and vacuum erection device for penile rehabilitation after laparoscopic nerve-preserving radical proctectomy for rectal cancer: a prospective controlled trial
publisher SAGE Publishing
series American Journal of Men's Health
issn 1557-9883
1557-9891
publishDate 2017-05-01
description The current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-intervention, nightly use of sildenafil 25 mg for 3 months after surgery, or concurrent use of nightly sildenafil 25 mg/day for 3 months and a vacuum erection device (VED) 10 to 15 minutes/day for 3 months—in a nonrandomized fashion. All participants had a follow-up of over 12 months prospectively, and patients had baseline, 3-, 6-, and 12-month assessment based on the International Index of Erectile Function–5 (IIEF-5). Seventy-one cases were included in final analyses. In the no-intervention group, the mean baseline IIEF-5 score of 21.9 decreased rapidly to 5.0 at 3 months ( p < .001), 9.2 at 6 months ( p < .001), and stayed at 10.9 at 12 months ( p < .001). In the single therapy group, the mean baseline IIEF-5 score of 22.4 decreased dramatically to 9.0 at 3 months ( p < .001), 14.9 at 6 months ( p = .005), and stayed at 15.1 at 12 months ( p = .005). In the combined therapy group, the mean baseline IIEF-5 score of 23.0 decreased slightly to 15.0 at 3 months ( p = .005), 18.0 at 6 months ( p = .038), and maintained at 18.7 at 12 months ( p = .163). Findings suggested an over 50% decline in the quality of erection function of the patients after LNRP. The early use of PDE-5i alone or combined use of PDE-5i and VED after LNRP maintained erectile function at 12 months.
url https://doi.org/10.1177/1557988316665084
work_keys_str_mv AT haijundengmdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
AT dongliumbbs phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
AT xiangmingmaomdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
AT xiaolianglanmd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
AT haoliumdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
AT guoxinlimdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial
_version_ 1724686776713347072